Press Releases

MCLEAN, Va., Jan. 8, 2020 /PRNewswire/ -- Dovel Technologies, a leading expert to federal agencies that blends deep domain expertise and advanced technologies in the health IT, life scienc

SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma (Meiji) as an exclusive distributor for its lymphoma product, HBI-8000, in Japan. Meiji also acquired exclusive rights for HBI-8000 in

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 /PRNewswire/ -- Genome Medical, a leader in telegenomics clinical care, today announced that it has expanded its commercial team to meet the growing demand from health care providers to integrate genomics into everyday care. Amy McLaughlin, newly appointed chief commercial officer, will lead the tea

LOS ALTOS, Calif., Jan. 8, 2020 /PRNewswire/ -- RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent 10,512,761 covering k

SOUTH SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gayle Crowell to its board of directors as an independent director. Ms. Crowell will serve on the

BOSTON, Jan. 8, 2020 /PRNewswire/ -- Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal en

CAMBRIDGE, Mass., Jan. 8, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced independent centrally reviewed top-line data for pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The data from t

MONTREAL and LAUSANNE, Switzerland, Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement 

KFAR SABA, Israel, Jan. 8, 2020 /PRNewswire/ -- Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption (IDE) application. With this IDE approval in hand, t

SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-106 in a Phase 1 dose-escalation clinical study. INBRX-106 is a novel, hexavalent agonist of OX40 in development for the treatment of solid tumor